Latest News and Press Releases

Hires Bring Four Decades of Investor Relations Experience and Strengthen Edison’s Roadshow Capability in North America NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Edison Group, a leading investor...

LONDON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Destiny Pharma is a virtual antimicrobial discovery company in Phase II clinical studies in the US. Destiny’s XF series of antimicrobial agents are novel,...

LONDON, Aug. 06, 2018 (GLOBE NEWSWIRE) -- The overall picture of improving global defence spending supports a return to organic growth for UItra. This is already reflected in the uplift seen in the...

LONDON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- The FDA’s sign off on Celyad’s first clinical trial design for its allogeneic NRK CAR T-cell therapy (CYAD-101) is an important milestone. The study,...

LONDON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- paragon’s continued strong growth is driven by the Electromobility division (Voltabox) and the smaller Mechanics division. With the Electronics division...

LONDON, July 18, 2018 (GLOBE NEWSWIRE) -- The next year is shaping up to be transformative for Oryzon with two data readouts from Phase IIa trials with ORY-2001 in Alzheimer’s disease (AD) and...

LONDON, July 16, 2018 (GLOBE NEWSWIRE) -- Transgene develops virus-based product candidates for use in oncology and infectious diseases, its five clinical products are currently in 11 clinical...

LONDON, July 16, 2018 (GLOBE NEWSWIRE) -- Basilea has successfully brought two anti-infective drugs to the market: Cresemba (severe mould infections) and Zevtera (bacterial infections). With the...

LONDON, July 13, 2018 (GLOBE NEWSWIRE) -- ReNeuron ended FY18 with a healthy cash balance and the 11 July announcement of an exclusivity agreement worth up to US$5m with a US specialty...

LONDON, July 13, 2018 (GLOBE NEWSWIRE) -- Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and...